CClinicalTrials.gg
RecruitingNCT03810482HTAPODOUpdated Sep 8, 2023

Pedometers and Walking Tests for Pulmonary Hypertension Patients

An interventional study of Pedometer and 6 minute walking test in Hypertension, Pulmonary, sponsored by University Hospital, Montpellier. Recruiting at 1 site in France. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-09-08.

Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Mar 2019; still recruiting 7 years 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Concordance between walking tests and pedometer data may seem like a logical outcome for pulmonary hypertension (PH) patients. However, many individuals have discordant results: results much worse or better during an in-hospital walking test as compared to real life activity.

The primary objective of this study is: to determine variables associated with discordance between the distance walked during an in-hospital 6-minute walking test (6MWT) and the average distance travelled per day (observed over a period of 28 days (2 × 14 days) using a pedometer) among PH patients.

Read the detailed description

Secondarily, the discordance between 6MWT results versus total pedometer recorded distance and versus maximum daily pedometer-recorded distance will be similarly studied. The aim of the study is also to search for variables associated with progression free survival. The relationships between pedometer data and self-reported dyspnea variation will be studied. Factorial analysis may be used to study the overall view of variable correlations and patient similarity/dissimilarity.

02

Conditions studied

  • Hypertension, Pulmonary

Keywords

  • health related quality of life
  • anxiety
  • depression
  • coping
  • fatigue
03

In context

Hypertension, Pulmonary

1,105 studies on the registry are indexed under Hypertension, Pulmonary; 234 are open to participants now.

This study's planned enrollment of 70 is above the median of 35 across 649 interventional studies indexed under Hypertension, Pulmonary.

Browse Hypertension, Pulmonary studies →

Lead sponsor

University Hospital, Montpellier is the lead sponsor of 1,244 studies on the registry; 225 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patient with idiopathic pulmonary hypertension (PH), familial PH, or PH associated with various pathologies (groups I to IV of the international classification)
  • New York Heart Association (NYHA) severity classes II to IV
  • Incident cases, or prevalent cases with stable disease over the last 3 months
  • Collection of informed written consent
  • Affiliation with or beneficiary of a social security program (health insurance)
  • Outpatient consulting at the hospital on the day of inclusion
  • 6 minute walking test on day of inclusion

Exclusion criteria

Exclusion Criteria:

  • Patients protected or unable to give consent according to Article L1121-8 of the French Public Health Code (CSP)
  • Pregnant or lactating women according to article L1121-5 of the CSP
  • Vulnerable persons according to article L1121-6 of the CSP
  • Simultaneous participation in any other research protocol
  • It is impossible to correctly inform the patient (language barrier, etc.)
  • The patient has already been included in the study
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    The study population

    The study population as described by eligibility criteria. Intervention: 6 minute walking test Intervention: pedometer

    Device: Pedometer · Other: 6 minute walking test

Interventions

  • DevicePedometer

    A pedometer will be worn by the patient at home for days 1 to 14 and 60 to 74.

  • Other6 minute walking test

    Performed according to current recommendations during routine visits (baseline and \~90 days for the purposes of this study).

06

What researchers measure

Primary outcomes

  1. The patient's discordance category as precisely defined here:

    Linear regression is performed for the distance walked during an initial 6 minute walking test (6MWT) and the average distance walked per day according to the pedometer intervention. The residuals from this regression will determine categories: Category 1 (pedometer high): the 25% of subjects not in category 2 and with higher values for pedometer data Category 2 (concordance): the 50% of included subjects with the smallest residuals in terms of absolute value. Category 3 (6MWT high): the 25% of subjects not in category 2 and with higher values for 6MWT data

    Time frame: 74 days

Secondary outcomes

  1. Health related quality of life questionnaire (the Medical Outcome Study - Short Form (SF36))

    This scale evaluates social, emotional and physical health of the patient through 11 questions.

    Time frame: Day 0

  2. Health related quality of life questionnaire (the Medical Outcome Study - Short Form (SF36))

    This scale evaluates social, emotional and physical health of the patient through 11 questions.

    Time frame: Month 3

  3. Hospital Anxiety and Depression (HAD) scale

    It is a questionnaire which detects if the patient is anxious or depressed through 14 questions.

    Time frame: Day 0

  4. Hospital Anxiety and Depression (HAD) scale

    It is a questionnaire which detects if the patient is anxious or depressed through 14 questions.

    Time frame: Month 3

  5. State-Trait Anxiety Inventory (STAI) questionnaire

    The State-Trait Anxiety Inventory is a 20 question-scale. For each question 4 levels of response are possible from 1 (never) to 4 (always).

    Time frame: Day 0

  6. State-Trait Anxiety Inventory (STAI) questionnaire

    The State-Trait Anxiety Inventory is a 20 question-scale. For each question 4 levels of response are possible from 1 (never) to 4 (always).

    Time frame: Month 3

  7. Multidimensional Fatigue Inventory (MFI)-20 questionnaire

    This questionnaire assesses the severity of the patient fatigue through 20 questions. For each question, 4 levels of response are possible : from "not at all" to "completely".

    Time frame: Day 0

  8. Multidimensional Fatigue Inventory (MFI)-20 questionnaire

    This questionnaire assesses the severity of the patient fatigue through 20 questions. For each question, 4 levels of response are possible : from "not at all" to "completely".

    Time frame: Month 3

  9. Coping with Health Injuries and Problems Scale

    This questionnaire assesses how the patient responds to health injuries and problems with 32 questions. For each question 5 levels of response are possible from 1 (not at all) to 5 (always).

    Time frame: Day 0

  10. Coping with Health Injuries and Problems Scale

    This questionnaire assesses how the patient responds to health injuries and problems with 32 questions. For each question 5 levels of response are possible from 1 (not at all) to 5 (always).

    Time frame: Month 3

07

Study locations

1 of 1 sites recruiting
  • Arnaud de Villeneuve Hospital
    Montpellier, 34295, France
    • Arnaud Bourdin, MD, PhD · Principal investigator
    • Clement Boissin, MD · Sub investigator
    • Anne Sophie Gamez, MD · Sub investigator
    • Romain Jean, MD · Sub investigator
    • Jérémy Charriot, MD · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03810482
Lead sponsor
University Hospital, Montpellier
Responsible party
Sponsor
First posted
Jan 18, 2019
Start date
Mar 21, 2019
Primary completion
Jun 21, 2024 (estimated)
Completion
Jun 21, 2024 (estimated)
Last update
Sep 8, 2023

Study contacts

Laurence Halimi, PhD, psychologist
Contact
l-halimi@chu-montpellier.fr
+33.(0)4.67.33.07.45
Arnaud Bourdin, MD, PhD
study director · University Hospitals of Monpellier

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion